- Home
- IMKTA vs GHRS Comparison
IMKTA vs GHRS Comparison
Compare IMKTA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMKTA
- GHRS
- Stock Information
- Founded
- IMKTA 1963
- GHRS 2018
- Country
- IMKTA United States
- GHRS Ireland
- Employees
- IMKTA N/A
- GHRS N/A
- Industry
- IMKTA Food Chains
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- IMKTA Consumer Staples
- GHRS Health Care
- Exchange
- IMKTA Nasdaq
- GHRS Nasdaq
- Market Cap
- IMKTA 1.2B
- GHRS 960.2M
- IPO Year
- IMKTA N/A
- GHRS 2021
- Fundamental
- Price
- IMKTA $67.14
- GHRS $17.57
- Analyst Decision
- IMKTA
- GHRS Strong Buy
- Analyst Count
- IMKTA 0
- GHRS 8
- Target Price
- IMKTA N/A
- GHRS $30.63
- AVG Volume (30 Days)
- IMKTA 114.7K
- GHRS 185.2K
- Earning Date
- IMKTA 08-07-2025
- GHRS 09-02-2025
- Dividend Yield
- IMKTA 0.99%
- GHRS N/A
- EPS Growth
- IMKTA N/A
- GHRS N/A
- EPS
- IMKTA 3.26
- GHRS N/A
- Revenue
- IMKTA $5,410,455,724.00
- GHRS N/A
- Revenue This Year
- IMKTA N/A
- GHRS N/A
- Revenue Next Year
- IMKTA N/A
- GHRS N/A
- P/E Ratio
- IMKTA $20.70
- GHRS N/A
- Revenue Growth
- IMKTA N/A
- GHRS N/A
- 52 Week Low
- IMKTA $58.92
- GHRS $6.00
- 52 Week High
- IMKTA $82.01
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- IMKTA 64.93
- GHRS 71.70
- Support Level
- IMKTA $65.83
- GHRS $15.25
- Resistance Level
- IMKTA $67.89
- GHRS $16.90
- Average True Range (ATR)
- IMKTA 1.45
- GHRS 1.22
- MACD
- IMKTA 0.11
- GHRS 0.28
- Stochastic Oscillator
- IMKTA 92.98
- GHRS 83.45
About IMKTA Ingles Markets Incorporated
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.